Research explores temporary effects of low-dose atropine in young adults

Published on May 11, 2026
A US study has found that a single drop of low-dose atropine causes changes in pupil size and focusing ability that persist for 24 hours
Continue reading on website
Other news

Developing new therapeutic options for diabetic retinopathy

May 8, 2026
Queen’s University Belfast researchers hope to develop a next-generation therapy that could help patients who do not respond to existing treatments

Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

May 11, 2026
BERLIN and SAN FRANCISCO—Bayer and Perfuse Therapeutics Inc. have announced an agreement under which Bayer said it will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer, a global enterprise with core competencies in the life science fields of health care and nutr